Skip to main content
PharmaResearch Co., Ltd. logo

PharmaResearch Co., Ltd. — Investor Relations & Filings

Ticker · 214450 ISIN · KR7214450009 KO Manufacturing
Open in API
Filings indexed 258 across all filing types
Latest filing 2026-04-27 Report Publication Anno…
Country KR South Korea
Listing KO 214450

About PharmaResearch Co., Ltd.

https://pharmaresearch.co.kr/en/

PharmaResearch Co., Ltd. is a biopharmaceutical company specializing in regenerative medicine. It utilizes marine biotechnology to develop and commercialize refined raw materials for cell and tissue regeneration. The company's activities also encompass the manufacturing of medical devices and providing consulting services for the development, licensing, and registration of pharmaceuticals. PharmaResearch focuses on creating innovative biological products to enhance human health and quality of life.

Recent filings

Filing Released Lang Actions
결산실적공시예고
Report Publication Announcement Classification · 1% confidence The document is a short notice announcing the upcoming publication date for the company’s quarterly (1Q 2026) financial results rather than the results themselves. It provides the reporting period and the scheduled disclosure date, indicating it is an announcement of a forthcoming report. This matches the definition of a Report Publication Announcement (RPA).
2026-04-27 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a mandatory disclosure to regulatory bodies (Korea Securities and Futures Commission and Korea Exchange) detailing the ownership status and share transactions by an officer (“임원”) of PharmaResearch (파마리서치), including the acquisition of 350 shares. This matches the definition of Director's Dealing (insider share transactions by executives).
2026-04-09 Korean
기업가치제고계획(자율공시)
Regulatory Filings Classification · 1% confidence The document is a Korean self-disclosed “기업가치 제고 계획” (corporate value enhancement plan) outlining future strategic targets (global expansion, M&A, dividend policy, etc.). It is not an AGM presentation, earnings release, financial report, proxy statement, or specific financing notice and does not attach a full report. It is a general regulatory announcement that does not neatly fit any other category. Therefore it falls into the fallback category “Regulatory Filings (RNS).”
2026-03-30 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a formal disclosure of the results of the company’s annual general meeting held on March 27, 2026. It lists the approval of financial statements, dividend resolutions, the appointment of directors, vote counts and approval percentages for each proposal. This matches the definition for “Declaration of Voting Results & Voting Rights Announcements” (DVA), which covers official results from shareholder votes at general meetings. It is not the full AGM presentation, nor an annual report, but specifically the voting outcomes announcement.
2026-03-27 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 1% confidence The document is a statutory notification to the Financial Services Commission/Korea Exchange detailing the resignation and appointment of outside directors at the company’s shareholder meeting. It explicitly announces changes in the board of directors (one director’s resignation and two new appointments), matching the definition of a Board/Management Information filing. Therefore, it should be classified as MANG.
2026-03-27 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 1% confidence The document is a comprehensive 'Audit Report' (감사보고서) for PharmaResearch, covering the fiscal year 2025. It includes the independent auditor's report, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes to the financial statements. While it contains financial data, it is the formal audit report required by law, not a standalone financial supplement or a quarterly report. It fits the definition of an Audit Report (AR) as it provides the results of the audit and the audited financial statements. FY 2025
2026-03-19 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.